ArticleReviews in cardiovascular medicine2025
Point-of-Care Ultrasound Optimizes the Preoperative Use of Prostaglandin E1 in Infants With Transposition of the Great Arteries.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to determine the optimal dosages of prostaglandin E1 required to maintain a patent ductus arteriosus (PDA) in infants with transposition of the great arteries (TGA) based on point-of-care ultrasound (POCUS) findings. Methods: Infants with TGA were recruited from two groups (the historical control group and the POCUS group that received POCUS in combination with pulse oximetry saturation (SpO Results: A total of 150 patients were included in this study. The mean gestational ages were 38.6 weeks and 38.9 weeks, respectively, and the mean birth weights were 3.09 kg and 3.23 kg, respectively, in the control and POCUS groups. The rate of PGE1 prescriptions in the control group (93.3%) was higher than in the POCUS group (71.1%; Conclusion: POCUS can optimize the use of PGE1, reduce unnecessary usage, postpone the initiation of PGE1, minimize the maintenance dose, and reduce the impact dose. POCUS guidance enhances the safety and effectiveness of PGE1 in infants with TGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.